Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJames D. Mcininch, Anna Borodovsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the mannan binding lectin serine peptidase 2 gene (MASP2). The invention also relates to methods of using such RNAi agents to inhibit expression of a MASP2 gene and to methods of preventing and treating a MASP2-associated disorders, e.g., arthritis, IgA nephropathy, thrombotic microangiopathy, diabetic nephropathy and membranous nephropathy.
Claims20
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of mannan binding lectin serine peptidase 2 (MASP2) in a cell, wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding MASP2, and wherein the antisense strand comprises the nucleotide sequence set forth as SEQ ID NO:
- 93, 92, 100, 94, 96, 70, 71, 72, 76, or 83, and the sense strand comprises the nucleotide sequence set forth as SEQ ID NO:
- 47, 46, 54, 48, 50, 24, 25, 26, 30, or 37 that corresponds to the antisense sequence.
Dependencies are inferred from the claim text.